Cell Viability Assays Market Regional Analysis:
North American Market Insights
North America region is projected to account for 38% share of the cell viability assays market, supported by an increase in cancer cases and infrastructure for clinical and laboratory research with a quality that has not yet been achieved in North America. a projected 1,806,590 new instances of cancer were identified in the US in 2020, while 606,520 people passed away from the illness. Consequently, it is expected that growth in the product market will be driven by demand for cell-based therapies. The expansion of the research and development capability, coupled with increasing expenditure on developing healthcare infrastructure, has led to a growing need for cell viability assays.
APAC Market Insights
The cell viability assays market in Asia Pacific is attributed to have about 28% share during the forecast period. The growth of the market may be due to a growing government initiative, which seeks to inform people about an increasing incidence of cancer and different types of cell therapy available. In addition, the government in these areas makes a great deal of investment in research and development. However, cell therapies such as stem cell therapy are also being funded by a variety of private sectors. Consequently, the growth of the market in this region is estimated to be stimulated by these factors. In addition, the growth of this industry is projected to be driven by an increase in demand for biopharmaceutical products as well as a presence of cutting-edge research and healthcare infrastructure throughout the region.
